In summary, our findings indicate that pericyte‐derived IL32 activates the β5‐integrin mediated Src‐Akt signaling pathway, thereby negating the inhibitory effects of TKIs on this pathway in EGFR‐mutated cancer cells. The gene discussed is AKT1; the disease is cancer.